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Extensive epidemiological studies in the last few decades
have indicated that regular consumption of certain vege-
tables, fruits and spices that are known to contain can-
cer chemopreventive agents like quercetin, resveratrol,
curcumin, and genistein can reduce the risk of cancer
[1–4]. These natural dietary agents, which have negli-
gible toxicity, can induce apoptosis in a variety of cancer
cells [1–4]. Further, these agents are considered as phar-
macologically safe because these are derived from nat-
ural sources that people use regularly as part of their
food intake. The most studied dietary compound is cur-
cumin (Fig. 1A), a natural polyphenolic compound ori-
ginally isolated from the rhizomes of Curcuma longa.
Curcumin has been used in Indian and Chinese tradi-
tional medicine for hundreds of years [2,3,5]. Curcumin
has been shown to act as a potent anti-inflammatory
and antioxidant agent [5–7]. It has generated great
attention as a possible novel anticancer agent because of
its encouraging antitumor activity and negligible toxicity
in animal models [2–5]. Further, several clinical trials
have shown that curcumin has negligible dose limited
toxicity even when curcumin was administered at doses
as high as 4–8 g per day [8,9]. Curcumin inhibits growth
of several types of cancer cells including breast, colon,
colorectal, basal cell carcinoma, and prostate cancer
cells and induces apoptosis in these cells [5,7,10–13]. It
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Curcumin, a component of turmeric, has potent antitumor activity against
several tumor types. However, its molecular target and mechanism of anti-
proliferative activity are not clear. Here, we identified curcumin as a novel
antimicrotubule agent. We have examined the effects of curcumin on cellu-
lar microtubules and on reconstituted microtubules in vitro. Curcumin
inhibited HeLa and MCF-7 cell proliferation in a concentration-dependent
manner with IC50 of 13.8 ± 0.7 lm and 12 ± 0.6 lm, respectively. At
higher inhibitory concentrations (> 10 lm), curcumin induced significant
depolymerization of interphase microtubules and mitotic spindle microtu-
bules of HeLa and MCF-7 cells. However, at low inhibitory concentrations
there were minimal effects on cellular microtubules. It disrupted microtu-
bule assembly in vitro, reduced GTPase activity, and induced tubulin aggre-
gation. Curcumin bound to tubulin at a single site with a dissociation
constant of 2.4 ± 0.4 lm and the binding of curcumin to tubulin induced
conformational changes in tubulin. Colchicine and podophyllotoxin partly
inhibited the binding of curcumin to tubulin, while vinblastine had no
effect on the curcumin–tubulin interactions. The data together suggested
that curcumin may inhibit cancer cells proliferation by perturbing micro-
tubule assembly dynamics and may be used to develop efficacious curcumin
analogues for cancer chemotherapy.
Abbreviations
DAPI, 4¢,6-diamidino-2-phenylindole; DTNB, 5,5¢-dithiobis(2-nitrobenzoic acid); HIF-1, hypoxia-inducible factor-1; MAP, microtubule associated
protein; VEGF, vascular endothelial growth factor.
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has been shown to prevent tumor initiation, promotion,
metastasis, and angiogenesis in experimental animals
[7,14,15]. It also down regulates the expression of
P-glycoprotein and increases the sensitivity of the multi-
drug resistant human cervical carcinoma cells (KB-V1)
towards vinblastine [16]. Although curcumin possesses a
broad range of anticancer activities, its molecular mech-
anism of action and primary cellular target(s) in cancer
cells are not clear. Curcumin has been shown to arrest
the cells in G2-M phase in various cancer cells and to
disrupt the mitotic spindle structure in breast cancer
cells [5,10,12,17–19]. Recently, curcumin has been
shown to alter the expression of many genes, which
are crucial for the G2-M transition, including tubulin
and p53 suggesting that curcumin might act as an anti-
microtubule agent [19]. These reports encourage us to
investigate the effects of curcumin on the microtubule
cytoskeleton.
Microtubules are highly dynamic polymers made up
of ab-tubulin dimers and they are essential for a vari-
ety of biological functions, especially in governing the
segregation of chromosomes during mitosis [20,21].
Microtubules are considered to be very important tar-
gets for developing chemotherapeutic drugs [21,22].
Many microtubule targeted agents including taxol,
vincristine, vinblastine and estramustine have been
successfully used in the treatment of various forms of
cancers [21,22]. These agents perturb microtubule poly-
merization dynamics and arrest cells at mitosis. A large
body of evidence indicates that sustained mitotic block
by microtubule targeted drugs triggers cell killing by
apoptosis [21,22]. However, these drugs also cause
severe side-effects in the patients by targeting the nor-
mal dividing cells. In addition to severe harmful side-
effects, poor bioavailability and the development of
drug resistance limit their application [21,23]. For
example, taxol and vinblastine act as substrates for
multidrug resistance protein P-glycoprotein, which also
limit its efficacy [23]. So, the development of novel
agents that bind to tubulin but show negligible toxicity
would strongly improve the chemotherapeutic potential
in the treatment of cancer. While searching for novel
anticancer agents, we reasoned that curcumin could be
potentially useful in the treatment of cancers because
of its lack of toxicity and its broad range of antitumor
activity including its strong antiangiogenic properties.
In this study, we found that curcumin inhibited pro-
liferation of HeLa and MCF-7 cells and depolymerized
interphase and mitotic microtubules of both the cell
types. In vitro, curcumin was found to bind to tubulin,
induced tubulin aggregation and perturbed micro-
tubule assembly. The evidence presented in this study
suggests that curcumin inhibits cell proliferation and
triggers cell killing at least partly by perturbing micro-
tubule assembly and function through tubulin binding.
Its antimicrotubule activity as reported in this study,
its limited harmful side-effects as documented by sev-
eral investigators [2,8,9] and its ability to down regu-
late P-glycoprotein expression [23] together strongly
suggest that curcumin alone or in combination with
other antimicrotubule agents may be evaluated for its
clinical potential against several types of cancers.
Results
Effects of curcumin on HeLa and MCF-7 cell
microtubules
Curcumin inhibited proliferation of HeLa and MCF-7
cells with IC50 values of 13.8 ± 0.7 lm and
12 ± 0.6 lm, respectively (Fig. 1B). Under similar
conditions, vinblastine and colchicine inhibited HeLa
cell proliferation with IC50 values of 2 ± 0.2 nm and
14 ± 2 nm, respectively. Curcumin was previously
shown to inhibit cell cycle progression at G2-M and to
induce apoptosis [5,10,12,17–19]. Because many cyto-
toxic drugs induce G2-M arrest by targeting micro-
tubules [21,22,24,25], we wanted to examine whether
curcumin also targets microtubules. The effects of
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Fig. 1. Inhibition of cell proliferation by curcumin. (A) Chemical
structure of curcumin [1,7-bis (4¢-hydroxy-3¢-Methoxyphenyl)-1,6-
heptadiene-3,5-dione]. (B) Effects of curcumin on the proliferation
of HeLa and MCF-7 cells were determined using sulfurhodamine B
assay. Data represent mean ± SEM (n ¼ 6).
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curcumin on the interphase microtubules of HeLa and
MCF-7 cells were examined using immunofluorescence
microscopy (Fig. 2). Control cells showed typical inter-
phase microtubule organization. No effect of curcumin
on the interphase microtubule network was apparent
at curcumin concentrations below 10 lm. However, at
relatively higher curcumin concentrations (‡ 25 lm),
a significant reduction of microtubule density occurred
in both the cell types. A significant reduction in the
number of microtubules at the periphery of the cells
was apparent and the central networks were disorgan-
ized. For example, 25 lm curcumin that inhibited
HeLa cell proliferation by  78% significantly depoly-
merized interphase microtubules. Curcumin (40 lm)
strongly depolymerized interphase microtubule in both
the cell types.
The effects of curcumin on the mitotic spindle
organization of HeLa and MCF-7 cells are shown in
Fig. 3. Control metaphase cells exhibited normal bipo-
lar mitotic spindle organization with two prominent
poles (arrow). Further, in control cells chromosomes
were compact and properly aligned at the metaphase
plate. Curcumin perturbed microtubules and chromo-
some organization in the spindle. For example, 10 lm
curcumin, which inhibited proliferation of HeLa and
MCF-7 cells by  28% and  46%, respectively, exer-
ted strong disrupting effects on the spindle micro-
tubules in both the cell types. The spindle apparatus
appeared to be collapsed in the presence of curcumin.
Curcumin-treated mitotic cells contained significantly
shorter and fewer microtubules compared to vehicle-
treated cells. Curcumin also induced aggregation of
tubulin in the cells. In addition, it disorganized chro-
mosome alignment at the metaphase plates and the
condensed chromosomes appeared ball-shaped in the
presence of 10 lm curcumin. Thus, curcumin depolym-
erized spindle microtubule organization and disorgan-
ized metaphase plate of chromosomes at lower
concentrations than that was required to disrupt inter-
phase microtubules.
Control
A B
Control
25 µM 25 µM
40 µM40 µM
Fig. 2. Curcumin depolymerized interphase
microtubules of HeLa and MCF-7 cells.
Effects of 25 and 40 lM curcumin on micro-
tubule networks of HeLa (A) and MCF-7 (B)
cells are shown. Control indicates vehicle
(0.1% dimethylsulfoxide) treated cells.
Microtubule (red) and nucleus (blue) are
shown.
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Inhibition of tubulin assembly into microtubules
and induction of tubulin aggregation by
curcumin in vitro
Because curcumin depolymerized microtubules in
HeLa and MCF-7 cells, we examined the effects of
curcumin on microtubule polymerization in vitro. We
used two complementary approaches, light scattering
and sedimentation, to analyze the ability of curcumin
to inhibit polymerization of phosphocellulose-purified
tubulin into microtubules in vitro. Curcumin inhibited
the rate and extent of the light scattering signal of tub-
ulin assembly in a concentration dependent manner
(Fig. 4A). For example, 50 lm curcumin decreased the
final extent of the light scattering signal of tubulin
assembly by  35%, while 100 lm curcumin reduced it
by  59% indicating that it inhibits tubulin assembly.
The effect of curcumin on the mass of assembled
polymers was determined by sedimentation. Curcumin
did not reduce the mass of sedimentable tubulin poly-
mers (Fig. 4B). Similar results were obtained when
polymerization was carried out with purified tubulin in
the presence of glycerol, dimethylsulfoxide, Taxol,
microtubule associated proteins (MAPs), or glycerol
seeds (data not shown).
The extent of light scattering signal depends on the
size and shape of the polymers [26]. Therefore, the
decrease in the light scattering signal of tubulin assembly
B
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Fig. 3. Curcumin disrupts mitotic spindle
organization. Effects of 10 lM curcumin on
microtubules and chromosome organization
of HeLa (A) and MCF-7 (B) cells are shown.
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Fig. 4. Inhibition of microtubule assembly by curcumin in vitro. (A) Effect of curcumin on microtubule polymerization kinetics was assessed
by monitoring the increase in light scattering at 550 nm. Control (s), 10 (d), 25 (n), 50 (m), and 100 (j) lM curcumin. Data are the average
of three independent experiments. (B) Curcumin did not change the sedimentable polymer mass appreciably. Data shown is mean ± SEM
(n ¼ 4). (C) Microtubules in the absence and presence of curcumin as visualized by electron microscopy. Images were taken at 43 000·
magnification. (D) Curcumin induced association of tubulin dimers (10 lM) was monitored using dynamic light scattering at 90. Data are
mean ± SEM (n ¼ 4).
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in the presence of curcumin could be due to the forma-
tion of very short microtubules, altered polymer mor-
phology or formation of small aggregates of tubulin.
To distinguish among these possibilities, polymers
formed in the presence of curcumin were examined by
electron microscopy. Consistent with previous reports
[27], tubulin polymerized in the presence of 1 m glu-
tamate formed mainly open sheets of parallel protofila-
ments (Fig. 4C). In the presence of 100 lm curcumin,
peeling of protofilaments was observed and large proto-
filaments were fragmented into small protofilaments.
In addition, aggregates of tubulin were found to be
abundant in the presence of 100 lm curcumin
(Fig. 4C). Curcumin induced aggregation of tubulin
dimers was further shown by dynamic light scattering
(Fig. 4D). In the absence of curcumin, the size of a
tubulin dimer was found to be 8.4 ± 1.8 nm. Incuba-
tion of tubulin with different concentrations of curcu-
min increased the size of the aggregates. For example,
the sizes of the tubulin oligomers were found to be
19 ± 5 nm, 36 ± 6 nm and 80 ± 17 nm in the pres-
ence of 25, 50, and 100 lm curcumin, respectively.
Copolymerization of curcumin into tubulin
polymer
The sedimented protein polymers were yellowish in
color, suggesting that the polymers and aggregates that
were formed in the presence of curcumin might be
composed of tubulin–curcumin complexes. To analyze
whether curcumin could incorporate into the tubulin
polymer as tubulin–curcumin complex, we first pre-
pared pure tubulin–curcumin complexes as described
below. Then, tubulin was polymerized in the presence
of low concentrations (1–6 lm) of tubulin–curcumin
complex. At this concentration range, curcumin did
not induce detectable depolymerization and aggrega-
tion of tubulin dimers. Tubulin–curcumin complex was
found to be incorporated into the polymers in a con-
centration dependent fashion (Fig. 5A). The stoichio-
metries of curcumin incorporation per tubulin dimer in
the microtubule were found to be 0.11 ± 0.03 and
0.32 ± 0.05 in the presence of 1 and 6 lm of curcu-
min, respectively. The results suggest that incorpor-
ation of curcumin in the microtubule altered polymer
morphology and perturbed microtubule assembly
dynamics.
Inhibition of GTP hydrolysis and induction of
conformational changes in tubulin by curcumin
Many microtubule-targeted agents inhibit the functions
of microtubules by modulating its GTPase activity
during assembly [21,25]. Curcumin inhibited the GTP
hydrolysis rate of microtubule protein (tubulin plus
MAPs), albeit modestly (Fig. 5B). For example, 50 lm
curcumin reduced the rate of GTP hydrolysis of
microtubules by 21% from 7.1 ± 0.4 to 5.6 ± 0.5
lm mg-1Æmin-1, respectively (P < 0.01). Further, the
extent of GTP hydrolysis was inhibited by  22% in
the presence of 50 lm curcumin (P < 0.01) (Fig. 5B,
inset).
The sulfhydryl groups of tubulin are sensitive mark-
ers for studying tubulin conformational changes upon
ligand binding [24,25]. The effect of curcumin on the
conformation of tubulin was determined by using the
cysteine modifying agent 5,5¢-dithiobis(2-nitrobenzoic
acid) (DTNB). Curcumin reduced the number of
A
B
Fig. 5. Curcumin copolymerized into microtubule and inhibited GTP
hydrolysis. (A) Curcumin was incorporated into the microtubules
along with tubulin. Data represent mean ± SEM (n ¼ 4). (B) Curcu-
min inhibited the rate of GTP hydrolysis of microtubule polymeriza-
tion (n ¼ 11). Inset shows GTP hydrolysis at various curcumin
concentrations. Data are mean ± SEM (n ¼ 8). Microtubule protein
(1.8 mgÆmL)1) was polymerized in the absence and presence of
50 lM curcumin as described in Experimental procedures.
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cysteine residues accessible to DTNB; there were
13.2 ± 0.2 sulfhydryl residues accessible per tubulin
dimer in the absence of curcumin and 11.7 ± 0.4 resi-
dues per tubulin dimer in the presence of curcumin.
The difference in the number of modified cysteine resi-
dues in the absence and presence of curcumin was 1.5
(P < 0.01) indicating that the binding of curcumin
to tubulin induces a conformational change in the
tubulin.
Binding of curcumin to tubulin
Curcumin has weak fluorescence in neutral aqueous
buffer with an emission maxima at 540 nm (Fig. 6A).
When, curcumin was mixed with tubulin in a 1 : 1
molar ratio, its fluorescence intensity increased mark-
edly (Fig. 6A). For example, the fluorescence intensity
of 5 lm curcumin increased several-fold in the presence
of equimolar concentration of tubulin. The emission
spectrum of curcumin showed a blue-shift of 45 nm
upon binding to tubulin indicating that curcumin binds
to a hydrophobic region of tubulin. Figure 6B shows
the titration curve of a constant amount of tubulin
treated with various concentrations of curcumin. Scat-
chard analysis of the data yielded a linear plot with a
dissociation constant of 2.4 ± 0.4 lm and a stoichio-
metry of 0.6 ± 0.02 (Fig. 6B, inset). The binding of
curcumin to tubulin was also investigated by measur-
ing the effects of curcumin on the intrinsic tryptophan
fluorescence of tubulin. As shown in Fig. 6C, curcumin
reduced the intrinsic tryptophan fluorescence of tubu-
lin in a concentration-dependent manner. The double
reciprocal plot of the binding data (Fig. 6C, inset)
yielded a dissociation constant of 3.2 ± 0.5 lm, which
is in excellent agreement with the Kd obtained by the
curcumin fluorescence titration.
Characterization of the binding site for curcumin
We used the curcumin–tubulin complex fluorescence
to determine whether curcumin could bind to the
colchicine or vinblastine site on tubulin. We reasoned
that if either drug could inhibit the binding of curcu-
min to tubulin, it should decrease the development of
curcumin–tubulin complex fluorescence. The extent of
curcumin binding at various concentrations of colchi-
cine and podophyllotoxin is shown in Fig. 7A. Both
colchicine and podophyllotoxin inhibited the fluores-
cence of tubulin–curcumin complex modestly. For
example, 25 lm colchicine inhibited curcumin binding
to tubulin by  21% and similar inhibition of curcu-
min fluorescence was also observed when podophyllo-
toxin was used in the place of colchicine. These data
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Fig. 6. Characterization of curcumin binding to tubulin. (A) Change
in fluorescence spectra of curcumin after binding to tubulin (2 lM).
Excitation wavelength was 425 nm. (B) Curcumin binding to tubulin
was measured by fluorescence spectroscopy. The inset shows a
Scatchard plot of curcumin binding to tubulin (n ¼ 7). (C) Curcumin
reduced the intrinsic tryptophan fluorescence of tubulin (2 lM). One
of the four experiments is shown. The excitation wavelength was
295 nm. Inset shows the double reciprocal plot of binding of curcu-
min to tubulin (n ¼ 4).
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indicated that the binding site of curcumin on tubulin
may partly overlap with the binding site of colchicine
and podophyllotoxin. Alternatively, the binding of col-
chicine or podophyllotoxin to tubulin induced con-
formational changes in tubulin that reduced curcumin
binding to the protein. In support of the second possi-
bility, curcumin was found to bind to the preformed
tubulin–colchicine or tubulin–podophyllotoxin complex
(Fig. 7B). Further, 100 lm colchicine or podophyllo-
toxin could not displace curcumin from the preformed
tubulin–curcumin complex significantly. For example,
incubation of 100 lm colchicine or podophyllotoxin
with the preformed tubulin–curcumin complex for 1 h
at 37 C reduced the fluorescence intensity of the pre-
formed tubulin–curcumin complex only by 17% and
4%, respectively. Vinblastine did not affect the tubu-
lin–curcumin complex fluorescence indicating that cur-
cumin binding site was different from the vinblastine
binding site (Fig. 7C).
Discussion
In the present study, we found that the antiprolifera-
tive activity of curcumin correlates well with its ability
to depolymerize cellular microtubules. At its lowest
effective inhibitory concentration (at or near IC50)
range, curcumin strongly depolymerized mitotic micro-
tubules of both HeLa and MCF-7 cells. At its higher
effective concentration range (2 · IC50), curcumin
depolymerized interphase microtubules of both the cell
types. In vitro, curcumin bound to tubulin with high
affinity (Kd, 2.4 ± 0.4 lm), inhibited tubulin assembly
into microtubules, reduced GTPase activity and
induced aggregation of tubulin dimers.
Curcumin was found to be incorporated into micro-
tubules in high stoichiometry (Fig. 5A) indicating that
curcumin does not inhibit microtubule assembly by the
‘end poisoning mechanism’ as described for colchicine
and vinblastine [21]. Although colchicine and podo-
phyllotoxin partly inhibited curcumin binding to tubu-
lin, the results obtained in this study indicate that
these agents inhibit microtubule polymerization by a
different molecular mechanism than that of curcumin.
There are several possible mechanisms through which
curcumin could inhibit microtubule polymerization.
One possibility is that curcumin–tubulin complex gets
incorporated into the microtubule lattice in large num-
bers and the incorporation of curcumin into the poly-
mers alters the geometry of the microtubules that
inhibits assembly. Another possibility is that curcumin
induces conformational change in the microtubule,
which alters its association with other accessory pro-
teins. Alternatively, curcumin can sequester tubulin
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Fig. 7. Competition of curcumin with microtubule inhibitors for tub-
ulin binding. (A) Colchicine and podophyllotoxin weakly inhibited
binding of curcumin to tubulin. Data represent mean ± SEM
(n ¼ 4). (B) Binding of curcumin to the preformed tubulin–colchicine
or tubulin–podophyllotoxin complex. Shown are emission spectra of
free curcumin (n), tubulin plus curcumin (s), tubulin–colchicine
complex plus curcumin (d) and tubulin–podophyllotoxin complex
plus curcumin (m). (C) Vinblastine did not inhibit the binding of cur-
cumin to tubulin. Data are average of three independent experi-
ments.
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dimers and the sequestration of tubulin reduces free
tubulin concentration for microtubule formation.
Several antimicrotubule agents such as noscapine,
estramustine, cematodin and griseofulvin did not inhi-
bit polymer mass significantly but they were shown
to suppress microtubule dynamics strongly [28–31].
Curcumin perturbed microtubule assembly, reduced
GTPase activity of microtubules, induced aggregation
of tubulin dimers, and depolymerized both interphase
and mitotic microtubules in cells indicating that cur-
cumin may perturb microtubule dynamics. Further,
2-Methoxyestradiol is also known to copolymerize into
microtubules stoichiometrically without affecting the
microtubule polymer mass appreciably [32], indicating
that both 2-Methoxyestradiol and curcumin might
affect the microtubule assembly dynamics in a similar
manner.
Curcumin is also shown to be a potent inhibitor of
angiogenesis, an essential process in growth and meta-
stasis of solid tumors [14,15]. This process requires
migration, proliferation, and capillary formation by
endothelial cells. Endothelial cells are stimulated by
hypoxia-inducible factor-1 (HIF-1) and vascular endo-
thelial growth factor (VEGF), and also active involve-
ment of cytoskeleton [14,33]. Agents that inhibit the
activity of HIF-1 and VEGF are considered as a
potential antiangiogenic agent [33]. More recently,
Mabjeesh et al. found that the disruption of the inter-
phase microtubule cytoskeleton by 2-Methoxyestradiol
inhibited HIF-1 activity [34]. Although the exact mech-
anism of antiangiogenic action of curcumin is not
known, it has been suggested that curcumin inhibits
angiogenesis by inhibiting HIF-1 and VEGF produc-
tion in tumor cells [14,35]. We found that curcumin
depolymerized interphase microtubules of both MCF-7
and HeLa cells. Thus, similar to 2-Methoxyestradiol
[34], curcumin may also inhibit HIF-1 activity by per-
turbing microtubule assembly.
Curcumin is known to have a broad spectrum anti-
cancer activity and it perturbs numerous signaling
pathways [3–5,35]. Although curcumin was found to
perturb microtubule assembly in cells and in vitro by
binding to tubulin, the data presented in the study can-
not exclude the involvement of other cellular targets
for curcumin. The role of microtubules in signal trans-
duction and intracellular transport are widely accepted.
Hence, it would be reasonable to think that the modu-
lation of the signaling pathways in cancer cells by
curcumin may involve microtubule perturbation.
In brief, the study shows that curcumin inhibits
microtubule assembly in HeLa and MCF-7 cells by
perturbing microtubule assembly dynamics. Our find-
ings support the development of curcumin and its ana-
logs as novel anticancer agents for the treatment of
several types of cancer including breast and cervical
cancers.
Experimental procedures
Chemicals and antibodies
Curcumin, GTP, Pipes, sulfurhodamine B, colchicine,
podophyllotoxin, vinblastine and 4¢,6-diamidino-2-phenyl-
indole (DAPI) were obtained from Sigma (St Louis, MO,
USA). Phosphocellulose (P11) was purchased from What-
man (Maidstone, UK). P-6 resin was purchased from Bio-
Rad (Hercules, CA, USA). The primary mouse monoclonal
antibody against a-tubulin was from Sigma. Secondary
antibody used in this study was goat antimouse IgG-Alexa-
568 (Molecular Probes, Eugene, OR, USA).
Cell culture and proliferation assay
HeLa and MCF-7 cells were grown in minimal essential
medium (Himedia, Mumbai, India) supplemented with 10%
(v ⁄ v) fetal bovine serum, kanamycin (0.1 mgÆmL)1), peni-
cillin G (100 unitsÆmL)1), and sodium bicarbonate
(1.5 mgÆmL)1) at 37 C in 5% CO2. Cell proliferation was
determined by a standard sulforhodamine B assay as des-
cribed previously [36]. Cells were incubated with different
concentrations of curcumin, vinblastine and colchicine for
one cell cycle (HeLa; 20 h, and MCF-7; 48 h) before fix-
ation and staining with sulforhodamine B.
Immunofluorescence microscopy
Immunofluorescence microscopy was performed as des-
cribed previously [24]. Briefly, cells were seeded on cover-
slips at a density of 25 000 cells per well in 24-well plates.
Cells were fixed and nonspecific antibody binding sites were
blocked by incubating with 2% BSA in NaCl ⁄Pi at 37 C
for 15 min. Further, cells were incubated for 2 h at 37 C
with antia-tubulin IgG (1 : 150 dilution) followed by a
1 : 100 dilution of Alexa568-conjugated secondary anti-
body. Then, the coverslips were rinsed with 2% BSA ⁄
NaCl ⁄Pi for 10 min and incubated with DAPI (1 lgÆmL)1)
for 30 s. Images were taken by using a Nikon (Kanagawa,
Japan) inverted microscope (TE2000) with a 40· objective
and analyzed by image pro plus software (Media Cyber-
netics, Silver Spring, MD, USA).
Purification of tubulin
Goat brain microtubule protein was isolated by two cycles
of polymerization and depolymerization in the presence
of 1 m glutamate and 10% (v ⁄ v) dimethylsulfoxide in the
assembly buffer (25 mm Pipes, pH 6.8, 3 mm MgSO4, 1 mm
Perturbation of microtubule assembly by curcumin K. K. Gupta et al.
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EGTA, 1 mm GTP, 1.0 m monosodium glutamate, pH 6.8)
[37]. MAP-free tubulin was purified from the microtubule
protein by phosphocellulose chromatography [25]. Protein
concentration was determined by the method of Bradford
using BSA as standard [38].
Spectral measurements
Absorbance measurements were performed in a JASCO
(Tokyo, Japan) V-530 UV-visible spectrophotometer using
a cuvette of 1 cm path length. All fluorescence measure-
ments were performed using a fluorescence spectrophoto-
meter (JASCO FP-6500) equipped with a constant
temperature water-circulating bath. To minimize the inner
filter effects at high curcumin concentrations, a 0.3 cm path
length cuvette was used for all fluorescence measurements.
The inner filter effects were corrected using the formula
Fcorrected ¼ Fobserved  antilogðAexcitation þ AemissionÞ=2
Inhibition of purified tubulin assembly
by curcumin
The kinetics of tubulin polymerization was monitored by
90 light scattering at 550 nm using a fluorescence
spectrophotometer [26]. Tubulin (12 lm) was mixed with
different concentrations of curcumin (0–100 lm) in the
assembly buffer and the assembly reaction was initiated
by incubating the sample at 37 C. The effect of curcumin
on the polymerized tubulin was determined by sedimenta-
tion. The microtubule polymers were collected by sedi-
mentation (128 000 g) for 40 min at 32 C. The tubulin
concentration in the pellet was determined by Bradford
method [38].
Electron microscopy
Tubulin (12 lm) was polymerized in the absence and pres-
ence of curcumin as described above. Microtubules were
fixed with prewarmed 0.5% glutaraldehyde for 5 min. Sam-
ples (20 lL) were applied to carbon-coated electron micro-
scope grids (300 mesh size) for 30 s and blotted dry. The
grids were subsequently negatively stained with 1% uranyl
acetate solution for 30 s and air-dried. The samples were
viewed with a Tecnai G212 electron microscope (FEI, Eind-
hoven, the Netherlands).
Estimation of tubulin aggregate size
Dynamic light scattering was used to determine the size of
tubulin aggregates in the presence of curcumin. Tubulin
was thawed and sedimented at 128 000 g to remove aggre-
gates. Tubulin (10 lm) was incubated in the absence and
presence of different concentration of curcumin for 10 min
at 4 C. The scattered light intensity was monitored at
25 C at an angle of 90 using a Zeta Plus Analyzer
(Brookhaven Instruments Corporation, Holtsville, NY,
USA). A 1.0 cm path length quartz cuvette was used for
the experiment.
Stoichiometry of tubulin–curcumin complex
incorporation into microtubules
To measure the incorporation of tubulin–curcumin complex
into microtubule polymers, first tubulin (40 lm) was incu-
bated with 80 lm curcumin for 10 min at 4 C to form tub-
ulin–curcumin complex. The mixture was passed through a
P-6 size exclusion column at 4 C to separate the unbound
curcumin. Tubulin containing fractions were centrifuged at
4 C for 20 min at 128 000 g and supernatants were used
for further experiments. Various concentrations of tubulin–
curcumin complex with unlabelled tubulin (final concentra-
tions of tubulin of 10 lm) were allowed to polymerize in
the assembly buffer at 37 C for 40 min. Polymers were col-
lected by centrifugation (128 000 g) at 32 C for 40 min.
Pellets were washed with prewarmed 1 m glutamate buffer.
Pellets were dissolved in buffer A (25 mm Pipes, pH 6.8,
3 mm MgSO4 and 1 mm EGTA). Curcumin concentration
was determined by measuring absorbance at 425 nm and
protein concentration was determined by the Bradford
method [38]. The background absorbance of curcumin was
determined using BSA instead of tubulin and it was found
to be less than 1% of the signal.
Measurement of GTPase activity
The standard malachite green sodium molybdate assay
was used to estimate the amount of Pi released during
GTP hydrolysis [39]. Microtubule protein (1.8 mgÆmL)1)
was incubated with 50 lm curcumin at 0 C for 10 min.
Then polymerization reactions were initiated by incuba-
ting the samples at 37 C with 1 mm GTP. At the desired
time points, 50 lL samples were removed and processed
for the malachite green assay as described previously
[25,39].
Titration of tubulin sulfhydryl groups
The sulfhydryl-specific reagent DTNB complexes with thi-
ol groups in tubulin [24,25]. The rate and extent of sul-
fhydryl-group modification by DTNB in the absence and
presence of curcumin were monitored by measuring the
absorbance changes at 412 nm [24,25]. Tubulin–curcumin
complex were prepared as described in the previous
experiment of copolymerization. The number of sulfhyd-
ryl groups modified after 40 min of reaction was deter-
mined by using a molar extinction coefficient of 12 000
for DTNB at 412 nm.
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Binding measurements by fluorometric titration
Fluorescence of curcumin
The increased curcumin fluorescence at 495 nm upon bind-
ing to tubulin was used to determine the affinity of curcu-
min with tubulin. Tubulin (2.0 lm) was allowed to react
with varying concentrations of curcumin (0.5–10 lm) in
buffer A at 25 C for 40 min. The excitation and emission
wavelength were 425 nm and 495 nm, respectively. The dis-
sociation constant (Kd) and number of curcumin binding
sites (n) on the tubulin were determined by the method des-
cribed by Hiratsuka [40]. Briefly, the fluorescence of curcu-
min was measured in the presence (F) and absence (Fo) of
tubulin, and the ratio of fluorescence (F ⁄Fo) was used to
calculate [curcumin]bound from
½curcuminbound ¼ ½curcumintotal=Q 1ðF=Fo  1Þ
where, Q is the enhancement factor of curcumin fluores-
cence for bound ligand. Q was measured by titrating a fixed
amount of curcumin (1.0 lm), with increasing amounts of
the tubulin in a concentration range of 2–12 lm. A double-
reciprocal plot of total protein concentration versus
observed fluorescence was extrapolated to infinite protein
concentration in order to determine the value of Q.
Enhancement factor, Q, of curcumin was 107. The amount
of free curcumin is obtained from the difference of the total
curcumin and calculated bound curcumin. The data were
analyzed in terms of the Scatchard equation [41],
B=½FT ¼ n=Kd  B=KdT
Where, [F] is the free curcumin concentration, B and T are
amounts of bound curcumin and total tubulin, respectively,
n is the number of binding sites, and Kd is the dissociation
constant for the tubulin–curcumin complex.
Quenching of the protein fluorescence
We used intrinsic tryptophan fluorescence of tubulin to
measure the binding affinity of curcumin to tubulin. Tubu-
lin (2 lm) was incubated with varying concentrations of
curcumin (0–10 lm) at 25 C for 40 min. The fluorescence
measurements were performed using 295 nm as the excita-
tion wavelength. The data were analyzed as described
previously [24,25]. The dissociation constant (Kd) was deter-
mined using the relationship, 1 ⁄B ¼ 1+Kd ⁄F, where F
represents free curcumin concentration and F ¼ C–B [Y],
where C is total concentration of curcumin and [Y] is the
molar concentration of ligand binding sites assuming a sin-
gle binding site per tubulin dimer [24,25].
Competitive binding assay
The ability of curcumin to compete with colchicine, podo-
phyllotoxin and vinblastine for binding to tubulin was
assessed by measuring the change in the tubulin–curcumin
complex fluorescence. Tubulin (2 lm) was incubated with
different concentrations of colchicine and podophyllotoxin
(1–25 lm) for 1 h at 37 C. For vinblastine, tubulin (2 lm)
was incubated with different concentrations (5–50 lm) of
vinblastine at room temperature for 20 min. Then 10 lm
curcumin was added to all reaction mixtures and spectra
were recorded after 30 min incubation at 25 C by exciting
the samples at 425 nm.
Binding of curcumin to preformed tubulin–
colchicine or tubulin–podophyllotoxin complex
Tubulin (3 lm) was incubated in the absence and presence
of 100 lm colchicine or podophyllotoxin for 45 min at
37 C. Then, 3 lm curcumin was added to the reaction mix-
tures and incubated for an additional 15 min. The disso-
ciation constants for colchicine and podophyllotoxin
interactions with tubulin are reported to be 0.5 lm and
0.6 lm, respectively [42,43]. Therefore, under the experi-
mental conditions used, tubulin would be completely ligan-
ded with colchicine or podophyllotoxin. The reaction
mixtures were excited at 425 nm and the emission spectra
were recorded as described previously.
Statistical analysis
Data was analyzed using one-way anova. Data is expressed
as mean ± SE.
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